

# APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



12<sup>th</sup> September 2025

The Secretary,  
Bombay Stock Exchange Ltd (BSE)  
Phiroze Jheejheebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.

**Scrip Code - 508869**  
**ISIN INE437A01024**

The Secretary,  
National Stock Exchange,  
Exchange Plaza, 5th Floor  
Plot No.C/1, 'G' Block  
Bandra - Kurla Complex  
Bandra (E)  
Mumbai - 400 051.

**Scrip Code-**  
**APOLLOHOSP**  
**ISIN INE437A01024**

Dear Sir/Madam,

## Sub: Outcome of the Board Meeting

We wish to inform you that the Board of Directors of the Company at its meeting held today, has approved the following matters:

- a. Execution of definitive share purchase agreements for the acquisition of 41,650,368 equity shares aggregating to a 30.58% equity stake held jointly by the International Finance Corporation, Washington (IFC) and IFC EAF Apollo Investment Company (IFC EAF) in its subsidiary, Apollo Health and Lifestyle Limited (AHLL), for a total purchase consideration of Rs 12,540.68 million. The transaction closure is subject to approval being obtained from the Competition Commission of India.
- b. Setting up a Comprehensive Oncology facility including a Single Gantry Proton Proteus One System at Gurugram at an investment of Rs 5,730 million.

The detailed disclosure as required under the aforesaid Regulation read with the SEBI Master Circular is enclosed herewith as Annexure I.

You are requested to kindly take note of the same.

The meeting of the Board of Directors commenced at 4.00 p.m and concluded at 6.50 p.m

Thanking You

Yours faithfully

For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN  
Sr. VICE PRESIDENT - FINANCE  
AND COMPANY SECRETARY



IS/ISO 9001 : 2000

### Regd. Office :

19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

### General Office :

"Ali Towers" III Floor,  
#55, Greams Road,  
Chennai - 600 006.

Tel : 044 - 2829 0956 / 3896 / 6681

Telefax : 044 - 2829 0956

Email : investor.relations@apollohospitals.com

Website : www.apollohospitals.com

# APOLLO HOSPITALS ENTERPRISE LIMITED

Annexure - I

CIN : L85110TN1979PLC008035



Sr. No	Particulars	Target Company								
		Apollo Health and Lifestyle Limited (AHLL)								
1	Name of the Target Company, details in brief such as size, turnover, etc	AHLL is engaged in the business of providing comprehensive, high quality healthcare services. The principal activities include operation of speciality hospitals, clinics, diagnostic centres, sugar clinics, dental clinics and dialysis centres.  The turnover of AHLL for the financial year ended March 31, 2025 was Rs 15,535 million on a consolidated basis								
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?  If yes, nature of interest and details thereof and whether the same is done at "arms length"	No. The transaction does not fall within the ambit of a related party transaction and no promoter group companies have any interest in AHLL								
3	Industry to which the entity being acquired belongs	Healthcare Services								
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The object is to consolidate ownership and have full control over AHLL's operations, enabling better integration with the Company's diagnostic services and improving operational efficiencies								
5	Brief details of any governmental or regulatory approvals required for the acquisition	Competition Commission of India								
6	Indicative time period for completion of the acquisition	The acquisition of the shares are expected to be completed by end of November 2025, subject to regulatory approvals and completion of customary closing formalities.								
7	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration								
8	Cost of acquisition or the price at which the shares are acquired	Rs 301.09 per share								
9	Percentage of shareholding/ control acquired and/or number of shares acquired	Upon completion of the Proposed acquisition of shares, AHLL will become a 99.42% Subsidiary of the Company with balance 0.58% held under ESOP pool.								
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	AHLL was incorporated under the Companies Act, 1956 on November 10, 2000. AHLL is currently engaged in providing retail healthcare services.  The turnover of AHLL for last 3 years is given below: <table><tr><th>Year</th><th>Turn-over (Rs. in Million)</th></tr><tr><td>2024-25</td><td>15,535</td></tr><tr><td>2023-24</td><td>13,653</td></tr><tr><td>2022-23</td><td>12,311</td></tr></table>	Year	Turn-over (Rs. in Million)	2024-25	15,535	2023-24	13,653	2022-23	12,311
Year	Turn-over (Rs. in Million)									
2024-25	15,535									
2023-24	13,653									
2022-23	12,311									
IS 9001 : 2000		Country of presence of AHLL: India								

**Regd. Office :**

19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

**General Office :**

"Ali Towers" III Floor,  
#55, Greams Road,  
Chennai - 600 006.

Tel : 044 - 2829 0956 / 389676681

Telefax : 044 - 2829 0956

Email : investor.relations@apollohospitals.com

Website : www.apollohospitals.com





# APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



## Annexure II

### Details of proposed Comprehensive Oncology Centre including a Proteus One, Single Gantry Proton Beam Therapy Center

S.No	Particulars	Description
1.	Project	Comprehensive Oncology center with Proteus One, single gantry Proton Beam Therapy system
2.	Existing Chennai Proton Centre capacity	Meant for treating 850 patients per annum  Currently 500+ patients per annum are being treated
3.	Proposed Proton Centre capacity addition	Would enable an additional 350 patients being treated per annum
4.	Period within which the proposed capacity is to be added	By FY 2029
5.	Investment required	Rs 5,730 million
6.	Mode of Financing	Internal Accruals
7.	Rationale	To meet the need for Comprehensive Oncology Care



IS/ISO 9001 : 2000

#### Regd. Office :

19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

#### General Office :

"Ali Towers" III Floor,  
#55, Greams Road,  
Chennai - 600 006.

Tel : 044 - 2829 0956 / 3896 / 6681

Telefax : 044 - 2829 0956

Email : investor.relations@apollohospitals.com

Website : www.apollohospitals.com

## //Press Release//

### **Apollo Hospitals Enterprise Ltd (AHEL) to acquire 31% stake held by International Finance Corporation in Apollo Health & Lifestyle Limited (AHLL) for ₹1,254 Crore**

### **AHLL charts path for next phase of growth with Consumer-First philosophy and focused verticals of care**

**Chennai, India, 12<sup>th</sup> September 2025** – Apollo Hospitals Enterprise Ltd (AHEL), today announced its intention to acquire 31% stake held by International Finance Corporation in Apollo Health and Lifestyle Limited (AHLL), a subsidiary of AHEL for a consideration of ₹1,254 crore. Following the transaction, AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool, creating greater flexibility for sharper capital allocation, disciplined growth, synergy in operations with AHEL and improved return on capital employed (ROCE) across its businesses.

With full ownership, AHLL will sharpen its consumer-first philosophy, to deliver high-quality healthcare at the most convenient touchpoints, and at an affordable cost, through four focused verticals for out-of-hospital care:

1. Primary Care & Diagnostics
2. Birthing & Women's Health Centers
3. Ambulatory Care Centers
4. Dialysis & Dental Networks

Each of these verticals offers opportunity to drive focused growth strategies and value unlock.

#### **Strategic Growth Priorities:**

- **Primary Care & Diagnostics:** A segment projected to grow at high-teen CAGR, with a focus not only on core diagnostics and preventive health but also next-generation specialty testing (genomics, advanced molecular diagnostics, personalized health screens). This will enable Apollo to build a differentiated platform catering to India's evolving healthcare needs.
- **Birthing & Women's Health (Apollo Cradle):** Consolidate market leadership and enhance premium maternity, fertility and neonatal services across urban India.

IS/ISO 9001 : 2000

#### **Regd. Office :**

19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

#### **General Office :**

"Ali Towers" III Floor,  
#55, Greams Road,  
Chennai - 600 006.

Tel : 044 - 2829 0956 / 3896 / 6681

Telefax : 044 - 2829 0956

Email : [investorrelations@apollohospitals.com](mailto:investorrelations@apollohospitals.com)

Website : [www.apollohospitals.com](http://www.apollohospitals.com)





- **Ambulatory Care Centers:** Reposition as part of Apollo's hospital cluster strategy in key metros, with expanded services across urgent care, surgical care, and short-stay procedures—providing cost-efficient, proximity-based models that bring quality care closer to patients.
- **Dialysis & Dental Networks:** Scale independently and via partnerships, addressing large unmet demand in two high-growth healthcare segments.

AHLL is a key part of Apollo's network strategy. Through its large physical network and proximity to key neighbourhoods and markets, AHLL serves as the consumer gateway for the Apollo Hospitals Group and provides the foundation for delivery of seamless, integrated care by connecting all parts of the network.

As consumers become more discerning, and look for convenience, experience and affordability, with a high bar for quality, distributed formats of care with the Apollo DNA for clinical excellence will deliver differentiated consumer experience.

**Ms. Suneeta Reddy, Managing Director, Apollo Hospitals Enterprise Ltd, said** "This acquisition is a decisive step that will allow for sharper capital allocation and a greater focus on select high-potential segments. With disciplined growth, improved profitability, and enhanced return on capital employed (ROCE), we see AHLL becoming a value-accretive driver in Apollo's integrated healthcare portfolio."

**Ms. Sangita Reddy, Joint Managing Director, Apollo Hospitals Enterprise Ltd, added** "IFC has been a valuable partner providing patient capital and facilitated the growth of AHLL. By bringing AHLL fully into Apollo's fold, we are sharpening the business focus across its four verticals—primary care & diagnostics, birthing & women's health, ambulatory care, and dialysis & dental. This sharper focus will enable AHLL to scale more effectively, innovate faster, and serve patients with care models that are more personalized, accessible, and future-ready."

## Industry Outlook

India's out-of-hospital healthcare market is poised for strong growth:

- **Diagnostics & Primary Care:** Projected to grow at high-teen CAGR, supported by rising preventive health awareness, urbanization, and the adoption of advanced specialty tests like genomics and precision diagnostics.
- **Birthing & Women's Health:** Premium birthing and fertility services expanding at 12–14% CAGR, supported by increasing demand for quality maternal care and experience.

IS/ISO 9001 : 2000

### Regd. Office :

19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

### General Office :

"Ali Towers" III Floor,  
#55, Greams Road,  
Chennai - 600 006.

Tel : 044 - 2829 0956 / 3896 / 6681  
Telefax : 044 - 2829 0956  
Email : [investorrelations@apollohospitals.com](mailto:investorrelations@apollohospitals.com)  
Website : [www.apollohospitals.com](http://www.apollohospitals.com)



# APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



- **Ambulatory Care (Urgent & Surgical):** A globally proven model, expected to gain traction in India as hospital clusters adopt cost-efficient, short-stay, and proximity-based care delivery in metros and tier I cities.
- **Dialysis & Dental:** Both segments demonstrate high unmet demand—dialysis at ~15% CAGR driven by CKD prevalence, and dental poised for rapid formalization in a fragmented market.

## About AHLL

Apollo Health and Lifestyle Limited (AHLL), a subsidiary of Apollo Hospitals Enterprise Ltd, is one of the largest integrated retail healthcare platforms in India. Its network spans primary care, diagnostics, birthing centers, dental and dialysis facilities, redefining out-of-hospital care delivery models for millions of patients nationwide.



IS/ISO 9001 : 2000

---

**Regd. Office :**

19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

**General Office :**

"Ali Towers" III Floor,  
#55, Greams Road,  
Chennai - 600 006.

Tel : 044 - 2829 0956 / 3896 / 6681  
Telefax : 044 - 2829 0956  
Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website : [www.apollohospitals.com](http://www.apollohospitals.com)



## //Press Release//

### **Apollo Hospitals to set up a Comprehensive Oncology Centre including the next generation proton therapy at Gurugram, strengthening Oncology Leadership**

**Chennai, September 12, 2025:** Apollo Hospitals, the nation's foremost integrated healthcare provider, today announced plans to set up a 100-bed Comprehensive Oncology Centre at Gurugram integrating the most advanced next generation Proton Therapy System.

The centre will be set up as part of the Phase 2 expansion of its upcoming 500-bed hospital in Gurugram. The Phase 1 development at Gurugram is on track to be commissioned by end Q4 FY25 / Q1 FY26, while the Proton & Integrated Cancer Centre will follow, with completion targeted over the next four years.

#### **Cementing Apollo's pole position in Oncology:**

This will be Apollo's third Proton Therapy installation in India, following the success of its flagship Proton Center in Chennai, the first center in South Asia and the Middle East, which has already treated over 2,500 patients from 147 countries, and the second Proton installation underway at Jubilee Hills, Hyderabad, within a dedicated 70-bed comprehensive cancer centre. With Gurugram, Apollo is building a unique pan-India integrated oncology program, reinforcing its pole position in cancer care.

The advancements through technology, innovation & expertise is defining Apollo's relentless pursuit of excellence in cancer care. Proton therapy is an effective treatment primarily for tumors in Paediatric, Head and Neck, Central Nervous System, Bone and soft tissue, Prostate and a wide range of other tumors.

According to studies, the global burden of cancer is projected to increase to 21.4 million incident cases by 2030. As per a study published in [The Lancet Regional Health](#), worldwide in terms of absolute incidence number, following China and the US, India ranks third, contributing 7.5% of all new cancer incidences and is expected to grow to 1.5 million this year.

IS/ISO 9001 : 2000

**Regd. Office :**

19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

**General Office :**

"Ali Towers" III Floor,  
#55, Greams Road,  
Chennai - 600 006.

Tel : 044 - 2829 0956 / 3896 / 6681  
Telefax : 044 - 2829 0956  
Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website : [www.apollohospitals.com](http://www.apollohospitals.com)



## Pioneering the Future of Oncology in India

Cancer treatment modalities are undergoing rapid transformation, and Apollo is at the forefront of ushering in next-generation, personalized oncology care. The Gurugram Cancer Centre of the future will bring together:

1. **Next generation Proton Therapy** – the most advanced radiation technology, delivering precision therapy while sparing healthy tissue.
2. **Advanced multi system Robotics** – enabling minimally invasive cancer surgeries with enhanced precision.
3. **High-End Linear Accelerators**– for state-of-the-art image-guided and adaptive radiotherapy.
4. **Immunotherapy & Targeted Therapies** – offering cutting-edge treatment protocols tailored to each patient.
5. **Personalized & Genomics-Driven Medicine** – transforming outcomes by aligning treatment to the unique biology of every cancer.
6. **Bone marrow transplant and Car T cell therapies** - a boon to patients with blood disorders and complex malignancies

## Apollo's Oncology Growth Plan

With five large markets of strength —Chennai, Hyderabad, Mumbai ,Bengaluru and NCR, and upcoming investments in several other cities, Apollo is uniquely positioned to address India's growing cancer burden. These centers will anchor its integrated Pan India oncology program, combining cutting-edge technology, global protocols, and multidisciplinary expertise.

Apollo aims to double the scale of its oncology business to over ₹5,000 crore in 3–4 years, driven by high-end personalized care, precision medicine, and deeper penetration into India's largest metros, along with expansion of footprint in other cities.



IS/ISO 9001 : 2000

### Regd. Office :

19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

### General Office :

"Ali Towers" III Floor,  
#55, Greaves Road,  
Chennai - 600 006.

Tel : 044 - 2829 0956 / 3896 / 6681  
Telefax : 044 - 2829 0956  
Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website : [www.apollohospitals.com](http://www.apollohospitals.com)



**Dr. Prathap C Reddy, Founder-Chairman, Apollo Hospitals Enterprise Ltd, expressed his pride in Apollo's pioneering spirit, stating, "At Apollo, we are driven by an unyielding passion for excellence in healthcare. Our commitment is to ensure that India remains at the forefront of medical innovation, providing patients with access to the world's most advanced treatments. The addition of next generation proton therapy to our Apollo Proton Cancer Centres further solidifies our position as a global leader in Proton Therapy. This next-generation technology will allow us to achieve superior clinical outcomes and significantly improve the quality of life for cancer patients in India and beyond."**

**Dr. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Enterprise Ltd, highlighted the broader vision behind this collaboration, stating, "Cancer care is evolving rapidly, and at Apollo, we remain steadfast in our mission to stay ahead of this evolution. The introduction of the next generation proton therapy is a significant leap towards personalized, precise, and highly effective treatment for cancer patients. Through this project we will facilitate knowledge-sharing and training for oncologists, enabling the widespread adoption of advanced treatment modalities across the region" .**

#### **About Apollo Hospitals Enterprise Ltd (AHEL)**

Apollo Hospitals Enterprise Ltd is Asia's leading integrated healthcare provider with a robust network of hospitals, primary care clinics, pharmacies, and diagnostic centers. AHEL has pioneered several medical innovations in India, including the introduction of Proton Therapy, robotics, and advanced personalized cancer care. Its oncology program is among the largest in Asia, serving millions of patients with a mission to make world-class healthcare accessible to all.

#### **About Apollo Proton Cancer Centre**

Apollo Proton Cancer Centre is the first Proton Therapy Centre in South Asia & the Middle East, and India's first JCI-accredited Cancer hospital. With its widespread network across India, Apollo Cancer Centres has over 400 oncologists to oversee the delivery of high-end precision Oncology Therapy. Our oncologists deliver world-class cancer care following an organ-based practice under competent Cancer Management Teams (CMTs). This helps us in delivering exemplary treatment to the clinical outcomes.

IS/ISO 9001 : 2000

#### **Regd. Office :**

19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

#### **General Office :**

"Ali Towers" III Floor,  
#55, Greams Road,  
Chennai - 600 006.

Tel : 044 - 2829 0956 / 3896 / 6681  
Telefax : 044 - 2829 0956  
Email : investor.relations@apollohospitals.com  
Website : www.apollohospitals.com

